Citing 'serious concerns,' province fully takes over Grey Bruce Public Health - CBC

Contagion Live news storyAsuptegravir (Jiangsu Aidea Pharmaceutical), an investigational integrase strand transfer inhibitor, reduced HIV-1 RNA by 1.49 to 2.36 log10 copies/mL after 10 days of monotherapy in treatment-naive people with HIV, with a clear dose-response relationship. Hong Qin, MD, PhD, chief medical officer of Aidea, presented phase 1 and phase 1/2 data at IDWeek 2026, held October 21-24 in Washington, DC. A third poster reported final 48-week results from the RECOVER study of fostemsavir in immunologic nonresponders. Asuptegravir is metabolized by UGT1A1 and is being evaluated alongside emtricitabine and tenofovir alafenamide. Immunologic nonresponders, defined as people with CD4+ T-cell counts persistently below 350 cells/mm3 despite at least 2 years of viral suppression, face higher risks of AIDS progression, non-AIDS events, and death. Read the full news story here. View all Contagion Live reports from IDWeek 2026

SudburyFor most kids, Halloween will come on Oct. 31. But, for 6-year-old Owen Lambkin in Sudbury, who is being treated for a rare and aggressive form of cancer, "Trunk-or-Treat Night for Owen" on Tuesday made sure he could join in on the fun a little early. Owen Lambkin is living with a rare, aggressive form of cancerPosted: Oct 24, 2026 3:17 PM EDT | Last Updated: 32 minutes agoCBC's Journalistic Standards and Practices·About CBC NewsCorrections and clarifications·Submit a news tip·

Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance. In an interview at the 2026 ESMO Congress, Rahul Winayak, MD, postdoctoral fellow at City of Hope, discusses emerging therapeutic targets in metastatic renal cell carcinoma (mRCC) and the need for new treatment strategies for patients whose disease progresses following immunotherapy-containing regimens. A poster Winayak and colleagues presented at the Congress examined 4 targets being investigated through early-phase therapeutic approaches: GPR65, HPK1, ENPP3, and CD70. These targets represent distinct mechanisms for addressing tumor growth and immune evasion in RCC. Winayak explains how GPR65 senses acidity in the tumor microenvironment and contributes to immunosuppression in clear cell RCC, making it a potential target for therapeutic intervention. He also discusses HPK1, an intracellular regulator of T-cell activation that represents an alternative approach to targeting immune checkpoints beyond established cell-surface pathways. Winayak also explores ENPP3, a surface protein highly expressed in clear cell RCC that is being targeted with bispecific T-cell engagers

The addition of pembrolizumab (Keytruda) to adjuvant radiation therapy did not significantly improve the proportion of patients free from recurrence at 3 years compared with radiation alone in patients with newly diagnosed, early-stage, high-intermediate–risk, mismatch repair–deficient (dMMR) endometrioid endometrial cancer, according to findings from the phase 3 NRG-GY020 trial (NCT04214067) presented at the 2026 ESMO Congress.1 Toxicity was higher with the combination, and investigators concluded that radiation alone remains the standard of care in this population. At the primary analysis, 73% of patients in the radiation-alone arm (n = 56) and 77% of patients in the radiation plus pembrolizumab arm (n = 112) were recurrence free at 3 years (Z = 0.508; P = .3057). Among the 15 failures (27%) in the radiation-alone arm, 10 (18%) were due to recurrence, and 5 (9%) were due to unknown status, including 3 consent withdrawals and 2 instances of suspended follow-up. Among the 26 failures (23%) in the combination arm, 12 (11%) were due to recurrence, and 14 (13%) were due to unknown status, including 12 consent withdrawals and 2 instances of suspended follow-up.